PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways

Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy

(2014) Lei Chang et al.   CANCER AND METASTASIS REVIEWS

TGF-β Effects on Prostate Cancer Cell Migration and Invasion Are Mediated by PGE2through Activation of PI3K/AKT/mTOR Pathway

(2013) BaoHan T. Vo et al.   ENDOCRINOLOGY

MicroRNA 23b Regulates Autophagy Associated With Radioresistance of Pancreatic Cancer Cells

(2013) Peng Wang et al.   GASTROENTEROLOGY

Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway

(2013) Jie Ni et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Outcome and Toxicity for Patients Treated with Intensity Modulated Radiation Therapy for Localized Prostate Cancer

(2013) Sujay A. Vora et al.   JOURNAL OF UROLOGY

Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells

(2013) Weiwei Xiao et al.   PLoS One

Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance

(2013) L Chang et al.   Cell Death & Disease

Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?

(2012) Shengtao Zhou et al.   CANCER LETTERS

Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro

(2012) Hongtu Chao et al.   CANCER LETTERS

The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cellsin vitro

(2012) Lilian Amrein et al.   INTERNATIONAL JOURNAL OF CANCER

The mTOR Signalling Pathway in Human Cancer

(2012) Helena Pópulo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis

(2012) Jiezhong Chen et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

(2011) J. J. Wallin et al.   MOLECULAR CANCER THERAPEUTICS

Acute and Late Toxicity After Dose Escalation to 82 GyE Using Conformal Proton Radiation for Localized Prostate Cancer: Initial Report of American College of Radiology Phase II Study 03-12

(2010) John J. Coen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of γH2AX and Other Biomarkers of Double-Strand Breaks During Radiotherapy

(2010) Ali Sak et al.   SEMINARS IN RADIATION ONCOLOGY

PI3K inhibitors for cancer treatment: where do we stand?

(2009) Sauveur-Michel Maira et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH